Management of hypertriglyceridemia in the diabetic patient

Ishwarlal Jialal, William Amess, Manpreet Kaur

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


The hypertriglyceridemia of diabetes can be classified into mild to moderate (triglycerides between 150-499 mg/dL) and severe hypertriglyceridemia (triglycerides ≥500 mg/dL). As in any other individuals with hypertriglyceridemia, secondary causes need to be excluded. The management of severe hypertriglyceridemia (chylomicronemia syndrome) includes aggressive reduction of triglycerides with intravenous insulin, fibrates, omega-3 fatty acids, and/or niacin therapy to avert the risk of pancreatitis. In patients with mild to moderate hypertriglyceridemia, the treatment of choice is statin therapy to achieve the lowdensity lipoprotein (LDL) and non-high-density lipoprotein (HDL) target goals. The evidence base would favor niacin therapy in combination with statin therapy to achieve the goals pertaining to LDL cholesterol and non-HDL cholesterol. The data about the combination of fibrate therapy with statin therapy are disappointing.

Original languageEnglish (US)
Pages (from-to)316-320
Number of pages5
JournalCurrent Diabetes Reports
Issue number4
StatePublished - Aug 2010


  • Diabetes
  • Dyslipidemia
  • Fibrates
  • Hypertriglyceridemia
  • Niacin
  • Statins

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine


Dive into the research topics of 'Management of hypertriglyceridemia in the diabetic patient'. Together they form a unique fingerprint.

Cite this